Overall rank by patents
#26,269
of 50,000 tracked assignees
USPTO PatentsView assignee record - 10 granted patents across 4 technology areas, recorded in grant years 2020–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
The verdict
According to USPTO PatentsView, Excalibur ranks #26,269 of 50,000 tracked US assignees by granted-patent volume, with 10 patents across 4 technology areas.
USPTO PatentsView assignee plate
Corpus R26269 · US Corporation #26,269 · 10 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH
Nearest grant-volume peer: Etherdyne Technologies, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Excalibur Pharmaceut… · this assignee
35 score
3D Lighting Innovati… · lowest
7 score
What this shows Excalibur's Innovation Score is 34.7/100 (top 51% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Excalibur Pharmaceuticals, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). Peak complete grant year is 2021 (4 grants) versus a trough of 1 in 2020. By volume, Excalibur sits between Etherdyne Technologies, Inc. and Eyecue Vision Technologies Ltd..
Excalibur Pharmaceuticals, Inc. shows 5 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Etherdyne Technologies, Inc.
10 patents
Evolution Lighting, LLC
10 patents
Evolve Technologies, LLC
10 patents
Exacta Systems, LLC
10 patents
Excelfore Corporation
10 patents
Exnodes Inc.
10 patents
Expedite International
10 patents
EyeCue Vision Technologies Ltd.
10 patents
Excalibur Pharmaceuticals, Inc.
10 patents
What this shows Excalibur holds 10 patents at rank #26,273, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #26,273 in granted patent volume.
Other assignees with the most granted patents in Excalibur's primary technology class.
Excalibur's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
35 Top 51% higher than 49% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 1 | 10.0% |
| 2021 | 4 | 40.0% |
| 2023 | 3 | 30.0% |
| 2024 | 2 | 20.0% |
Top 4 of 4 technology areas
Overall rank by patents
#26,269
of 50,000 tracked assignees
34.7 out of 100
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.